Remote Patient Monitoring Devices Market Size, Share, Growth and Forecast, 2025-2035

Home care and wearables anchor connected monitoring

The global remote patient monitoring devices market was valued at USD 29.81 billion in 2025 and is projected to increase from USD 31.99 billion in 2026 to USD 60.30 billion by 2035, registering a CAGR of 7.30% during 2026–2035. Demand comes from people with high blood pressure, diabetes, heart rhythm disorders and lung disease whose physicians want daily readings between clinic visits, and from health systems that discharge patients earlier to home care. North America held the largest regional share, 43.0% in 2025, because Medicare and private insurers in the United States pay for device supply and monthly management. Asia Pacific is the fastest-growing region at 8.69% a year, as China, Japan and India expand connected care for aging populations. The commercial picture shifted in 2024, when U.S. regulators cleared the first over-the-counter glucose biosensors, and again in January 2026, when Medicare began paying for shorter monitoring periods. As a result, growth now depends on consumer sensors as much as clinical programs.

Which connected monitors does this analysis count?

The analysis counts vital sign monitors, blood glucose monitors, cardiac rhythm monitors, respiratory monitors, fetal heart monitors, prothrombin monitors and related hardware that transmit readings to clinicians from outside the hospital room. Wearable patches, watches and sensors, implanted cardiac monitors and handheld meters are included when they send data to a care team or patient app.

Software platforms sold without hardware, care management services, telehealth visits and inpatient bedside monitors that never leave the ward sit outside the value counted here. The value chain runs from sensor and device makers through distributors, health systems, home care agencies and pharmacies to payers and patients.

Vital sign monitors and wearables lead spending

Why do vital sign monitors lead product types?

Based on product, the market is categorized into vital sign monitors, blood glucose monitors, cardiac rhythm monitors, respiratory monitors, fetal heart monitors, prothrombin monitors and others. Vital Sign Monitors led with a 27.0% share of 2025 value, because blood pressure, pulse and oxygen readings anchor most home programs. Blood Glucose Monitors grow fastest at 8.43% a year, as over-the-counter biosensors reach adults who do not use insulin.

How far ahead are wearable monitors?

Based on modality, the market is categorized into wearable, implants and handheld products. Wearable products led with a 55.0% share of 2025 value, because patches, watches and arm sensors collect readings without patient effort. This modality also grows fastest at 8.00% a year, as sensor wear time lengthens. Handheld meters grow more slowly, because continuous sensors replace many fingerstick and spot-check readings.

Which conditions account for the most monitoring?

Based on application, the market is categorized into cancer, cardiovascular diseases, diabetes, weight management and fitness monitoring and others. Cardiovascular Diseases led with a 36.0% share of 2025 value, because high blood pressure and rhythm disorders affect very large populations. Weight Management and Fitness Monitoring grows fastest at 8.27% a year, as consumer glucose biosensors and connected scales reach people without a diagnosis.

Why do home care settings lead end users?

Based on end user, the market is categorized into hospitals, ambulatory surgical centers, specialty clinics, home care settings and others. Home Care Settings led with a 44.0% share of 2025 value, because most connected devices are used at home between visits. This end user also grows fastest at 8.16% a year, as health systems shorten hospital stays and move follow-up care into homes.

Chronic disease and Medicare payment lift demand

How does chronic disease prevalence sustain demand?

Chronic disease prevalence is the largest demand driver, because high blood pressure and diabetes need readings every day rather than once a quarter. The World Health Organization reports that about 1.4 billion people had hypertension in 2024 and that just over one in five had it under control. The WHO also counts about 830 million people with diabetes in 2022, and 59% of adults aged 30 and older with diabetes were not taking medication for it. In addition, 99 of 195 countries and territories report national hypertension control rates below 20%. As a result, physicians use home blood pressure cuffs and glucose sensors to find patients whose treatment needs adjusting.

Why has Medicare payment expanded clinical programs?

Medicare payment has expanded clinical programs, because separate codes pay for device supply and monthly review by care teams. A September 2024 federal oversight report, covered by the American Hospital Association, found that about 570,000 Medicare enrollees received remote monitoring in 2022. That figure was up from 55,000 in 2019, a more than tenfold increase in three years. The same report found that about 43% of enrollees did not receive all three components of the service, which points to room for fuller use. In turn, the United States remains the largest single country for paid monitoring programs, with physician practices and health systems both billing for the service.

Download Free Sample

How do shorter monitoring periods widen eligibility?

Shorter monitoring periods widen eligibility, because many patients do not need readings on 16 or more days each month. The Centers for Medicare & Medicaid Services now states that data must be collected for 2 to 15 or 16 or more days out of 30, depending on the code descriptor. The calendar year 2026 fee schedule, issued Oct. 31, 2025, took effect for services on or after Jan. 1, 2026. Coding guidance describes a new device supply code for 2 to 15 days and a management code for 10 to 19 minutes per month. Because of this, post-surgery and short-term cardiac patients now qualify for paid programs in home care settings.

Why does population aging lift long-term demand?

Population aging lifts long-term demand, because older adults live with more chronic conditions and leave the hospital sooner than in the past. World Bank data show that people aged 65 and older made up 22.4% of the European Union population in 2025. The same share was 18.6% in North America and 13.9% in East Asia and Pacific. Worldwide, the share reached 10.4% in 2025, which means a growing pool of patients with heart failure, lung disease and diabetes. As a result, home healthcare agencies and hospital discharge teams add connected scales, pulse oximeters and blood pressure cuffs for elderly patients.

Over-the-counter sensors and AI features reshape use

How is the rise of over-the-counter glucose sensors changing use?

A rise in over-the-counter glucose sensors is changing use, because adults can now buy continuous monitors without a prescription. On March 5, 2024, the FDA cleared the Dexcom Stelo biosensor as the first over-the-counter continuous glucose monitor for adults who do not use insulin. In June 2024, Abbott announced FDA clearance for Lingo and Libre Rio, two more over-the-counter systems based on its FreeStyle Libre sensors. Abbott says this technology is used by about 6 million people across more than 60 countries. In June 2026, the FDA extended Stelo to people aged 2 and older who do not use insulin. In turn, blood glucose monitors grow at 8.43% a year, the fastest product pace.

Is the shift to AI features in home monitors widening use?

The shift to AI features in home monitors is widening use, because one reading can now screen for more than one condition. In November 2024, Omron received FDA De Novo authorization for home blood pressure monitors with AI-based atrial fibrillation detection, and it announced plans to launch the monitors in the United States in early 2025. A study cited by Omron reported 95% sensitivity and 98% specificity for the feature. Omron also notes that about 40% of people with atrial fibrillation have no symptoms, so screening at home can find missed cases. Because blood pressure is measured daily, the feature adds rhythm screening at little extra cost. As a result, implantable cardiac monitors gain referrals once home readings flag irregular rhythms.

Download Free Sample

Where can consumer wellness sensors open new revenue?

Consumer wellness sensors open a clear opportunity, because people without a diagnosis now buy clinical-grade sensors at pharmacies and online. Abbott designed Lingo for adults aged 18 and older who do not use insulin and want to improve their overall health. In an Abbott study, 77.1% of Lingo biosensors lasted the full 14-day wear period. Stelo also serves people without diabetes who want to see how diet and exercise affect glucose levels. Because these buyers pay out of pocket, weight management and fitness monitoring grows at 8.27% a year, the fastest application. In turn, makers can sell subscriptions and apps alongside each sensor.

Can watches with clinical clearance link into hospital programs?

Watches with clinical clearance create a growth opening, because they combine consumer comfort with data that clinicians can use. In August 2024, Masimo announced FDA 510(k) clearance for its W1 medical watch to connect with the Masimo SafetyNet telemonitoring system. The watch reports blood oxygen saturation, pulse rate, perfusion index and heart rate derived from ECG. Its earlier clearance covers over-the-counter and prescription use at home and in hospitals. Wearable products already led modalities with 55.0% of 2025 value. As a result, telehealth programs can add wrist readings without separate bedside equipment, which lowers the cost of following each patient at home.

Billing oversight and data gaps slow adoption

How does billing oversight slow program growth?

Billing oversight slows program growth, because federal auditors now question how monitoring services are ordered and billed. The September 2024 oversight report recommended that Medicare require an order for monitoring and collect data on the equipment used and vitals measured. Providers that cannot document each step of the service face repayment risk. As a result, some practices delay new programs until billing rules and audit practices become clearer.

Why do incomplete programs reduce clinical value?

Incomplete programs reduce clinical value, because devices help only when someone reviews the readings and acts on them. About 43% of Medicare enrollees receiving monitoring in 2022 did not receive all three parts of the service. Patients may stop using a cuff or sensor after a few weeks when no one calls about results. However, shorter monitoring codes and automated alerts can keep more patients engaged.

Do connectivity gaps limit use in lower-income regions?

Connectivity gaps limit use in lower-income regions, because most devices need a phone, cellular link or home internet to send data. Many rural patients in Africa, South Asia and Latin America lack reliable coverage or cannot afford data plans. Device makers also face separate approval and data protection rules in each country. In turn, clinical programs there remain small and depend on grants or pilot funding.

Can accuracy limits weaken clinical trust?

Accuracy limits can weaken clinical trust, because consumer sensors are not designed for every patient group. The FDA notes that Stelo is not for people with problematic hypoglycemia, because it does not alert users to low blood sugar. Physicians must therefore match each device to the patient and confirm unusual readings. However, wider validation studies and clearer labeling can support broader use over time.

Medicare coverage keeps North America ahead

How does Medicare coverage keep North America ahead?

North America held a 43.0% share of 2025 value and grows at 6.79% a year through 2035. Medicare pays for device supply and monthly management, and enrollees using monitoring reached about 570,000 in 2022. The FDA has also cleared over-the-counter glucose sensors from Dexcom and Abbott since 2024. However, tighter billing oversight may slow growth for providers that run large programs without full documentation.

What makes Asia Pacific the fastest-growing region?

Asia Pacific held a 22.0% share of 2025 value and is the fastest-growing region at 8.69% a year. Japan has one of the oldest populations in the world, and Omron and Nihon Kohden supply home and clinical monitors from the country. Mindray serves Chinese hospitals and exports monitors to many regions. Because East Asia and Pacific already had 13.9% of its population aged 65 and older in 2025, demand for home readings rises quickly.

Download Free Sample

Why does Europe grow at a steadier pace?

Europe held a 26.0% share of 2025 value and grows at 6.69% a year, the slowest pace of the five regions. The European Union has the oldest population of any region in the World Bank data, at 22.4% aged 65 and older in 2025. However, national health systems pay for home monitoring through separate local programs, which slows uniform adoption. Philips, Dräger and Biotronik supply monitors and implanted devices from European bases.

How are Latin American health systems adopting connected care?

Latin America held a 5.0% share of 2025 value and grows at 7.89% a year through 2035. Private hospitals in Brazil and Mexico run home follow-up programs for cardiac and diabetic patients. As a result, wearable sensors and connected blood pressure cuffs spread first among insured urban patients.

Where do the Middle East and Africa stand on home monitoring?

The Middle East and Africa held a 4.0% share of 2025 value and grows at 7.79% a year through 2035. Gulf health systems invest in virtual hospitals and connected care, while much of Africa still lacks the connectivity and reimbursement needed for large programs.

Download Free Sample

Clearances and launches since 2024

Sensing and connectivity tools to watch

• Continuous glucose biosensors sit on the upper arm for up to 15 days and send readings to a phone app without fingersticks.
• Pulse wave rhythm algorithms analyze the pressure signal from a standard cuff reading, as Omron does with more than 300 mathematical indices.
• Medical-grade smartwatches combine optical sensors and ECG electrodes to report oxygen saturation and pulse to clinicians in remote settings.
• Cellular and Bluetooth gateways move readings from scales, cuffs and patches to care teams, so patients need no home computer or setup.

Device makers compete on accuracy and integration

Rivalry in connected monitoring turns on sensor accuracy, wear time, data integration and reimbursement support, because health systems buy complete programs rather than single devices. Abbott, Roche and Johnson & Johnson compete in glucose and blood testing, while Medtronic, Boston Scientific and Biotronik supply implanted cardiac monitors and remote follow-up. Philips, GE Healthcare, Mindray, Nihon Kohden, Dräger and OSI Systems sell vital sign and clinical monitors that link to hospital records. Omron and Welch Allyn focus on blood pressure and spot-check devices, and Masimo adds medical-grade watches. Honeywell, Smiths Medical, LifeWatch, American Telecare, Vitls and CareValidate serve home care, telehealth and patch-based monitoring niches. Each company now competes on how easily clinicians can review readings inside existing record systems.

Companies profiled and their roles in this market

Home use and payment rules set the pace to 2035

Credence Research expects home use and payment rules, rather than device innovation alone, to set the pace of growth through 2035. The market advances at 7.30% a year, as wearable sensors and home care programs add most new users. Over-the-counter glucose biosensors and AI-enabled blood pressure cuffs bring consumer buyers into a market once led by clinics. Makers that integrate readings into health records and support billing documentation should defend share, while sellers of standalone handheld meters face slower growth as continuous sensors replace spot checks.

How Credence Research sized connected monitor spending

The base year is 2025 and the forecast runs from 2026 to 2035. Market values come from the Credence Research model, which sums device spending by product, modality, application and end user across five regions. Splits by region and segment are Credence Research estimates, informed by World Health Organization disease data, World Bank population data, FDA clearances, CMS guidance, federal oversight findings and company releases. This edition relies on published sources only and did not use primary interviews or surveys.

Connected home monitoring outlook to 2035

The remote patient monitoring devices market is projected to reach USD 60.30 billion by 2035, with wearables and home care settings supplying most of the added value. Over-the-counter glucose biosensors will keep widening the buyer base, while shorter Medicare monitoring periods bring more short-term patients into paid programs. North America keeps the highest spending, and Asia Pacific adds the largest number of new users as populations age. As a result, accuracy, wear time and record integration will separate leaders from followers.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.